This study marks the first use of ocular spectroscopy to detect transthyretin (ATTR) amyloidosis, a rare but serious heart disease.

ATTR amyloidosis affects approximately 500,000 people worldwide and is often diagnosed late due to symptoms resembling other heart conditions. This disease is characterized by the buildup of amyloid proteins in the heart, leading to progressive heart failure and a significant reduction in life expectancy if not diagnosed and treated promptly.

Promising Technology for Early Diagnosis

The pilot study, led by Dr. Erwan Salaun, a cardiologist and researcher at the Institute, aims to use the Zilia Ocular, a next-generation retinal camera, to non-invasively detect early signs of transthyretin amyloidosis through a simple eye exam.

“The speed and accessibility of such a test could greatly improve the management of transthyretin amyloidosis,” emphasized Dr. Salaun. “Zilia’s technology provides us with new information that we hope will significantly improve access to care and prognosis for patients with this condition.”

The Eye as a Window to Health

Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia, commented on the significance of the study: “The eye is often considered a window into the health of a person. This research project, which has the potential to use the eye to non-invasively detect a major heart condition, showcases the enormous potential of our technology.”

About Zilia

Zilia is a medical technology company developing a groundbreaking platform to non-invasively measure biomarkers in the eye, with an initial focus on ocular oximetry. By integrating advanced photonics and artificial intelligence, Zilia’s first-of-kind technology is intended to leverage the eye’s optical properties and its direct connections to the vascular system and the brain, capturing critical information on ocular and overall health.

For Further Information

Zilia: https://ziliahealth.com/
IUCPQ-ULaval: https://iucpq.qc.ca/en/research/research-centre